Company* (Country; Symbol)


Type/Product Area

Terms/Details (Date)

Amarillo Biosciences Inc. (OTC BB:AMAR)

Gesellschaft Fur Medizinisch and Technische Investionen mbH & CoKG (Germany)

Amarillo entered a deal with Curtis Martin, CEO of the German venture capital firm, for commercialization of low-dose oral interferon

GMTI will work to commercialize the product in Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia; terms were not disclosed (11/30)

A.P. Pharma Inc. (APPA)

Paul Royalty Fund

The fund purchased future royalties on sales of the dermatology products Retin-A Micro and Carac

A.P. Pharma received $25M up front, and could get $5M more if four-year targets are hit; A.P. was entitled to royalties through deals with Johnson & Johnson and Sanofi-Aventis companies (1/18)

ChondroGene Ltd. (Canada; CDNX:CDG)

Kaiser Permanente

Deal to develop a research database infrastructure for use in genomic research

The principal objective of the database is to standardize and achieve consistency in the format of data for future studies; terms were not disclosed (10/28)

IT-omics* (France)

OmniViz Inc.*

Deal to integrate software for use in the drug discovery process

Terms of the deal were not disclosed; OmniViz focuses on visual informatics software (11/29)


* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board.